Recurrent Sinusitis with Elevated IgE + Bilateral Turbinate Hypertrophy - Harrison/MD Medicine Approach

Clinical Framework: What's Actually Going On

Step 1: Diagnosis Refinement - Is This Allergic CRS?

Diagnostic Criteria for CRS (EPOS/Goldman-Cecil, Table 394-5)

• Mucopurulent nasal drainage (anterior or posterior)
• Nasal obstruction/congestion
• Facial pressure/fullness
• Reduced sense of smell (hyposmia/anosmia)

• Nasal/middle meatus polyps on endoscopy
• Edema or purulence in middle meatus
• Paranasal sinus opacification on CT

Differentials to Exclude First (Goldman-Cecil Table 394-3)

Important: Elevated total IgE with specific unilateral expansion on CT should raise suspicion for Allergic Fungal Sinusitis (AFS) - characterized by elevated total IgE, specific IgE to colonizing fungi (Aspergillus, Alternaria), characteristic hyperdense mucin on CT, and eosinophilic mucin. This is a specific subtype requiring surgical management.

Step 2: Investigations (Systematic, MD Medicine Style)

A. Allergy Workup (Mandatory - Confirms Atopic Driver)

• Positive if wheal ≥3 mm larger than negative control
• Sensitivity 80-100%, specificity 70-90% (Cummings ORL)
• Stop antihistamines 2-7 days prior; stop omalizumab 8 weeks prior
• Tests for: house dust mite, cockroach, moulds (Alternaria, Aspergillus, Cladosporium), pollens (trees, grasses, weeds), animal dander

• Preferred if: severe dermatographism, active skin disease, inability to stop antihistamines, pregnancy
• Total IgE > 100 IU/mL is strongly suggestive of atopic disease

• More sensitive than SPT; used to determine immunotherapy starting dilution (endpoint dilution method)
• Reserved for when SPT is negative but clinical suspicion remains high

B. Nasal Assessment

• Assess turbinate size, mucosal pallor/edema (bluish/pale mucosa = allergic)
• Look for: nasal polyps (middle meatus), septal deviation, purulent discharge, allergic crease

• Distinguishes allergic rhinitis (eosinophils present) from NARES vs. vasomotor rhinitis

C. Imaging

• Bilateral turbinate hypertrophy confirmed
• Assess: degree of ostiomeatal complex (OMC) obstruction, air-fluid levels, mucosal thickening, polyps, bony erosion
• Lund-Mackay scoring for severity grading (each sinus 0-2; max 24)
• Look for: hyperattenuating mucin within sinuses (AFS), bony expansion/erosion

• Mucosal thickening >3mm = significant
• Complete opacification = advanced disease
• Hyperdense material within sinus cavity = fungal mucin (suggestive of AFS)

D. Laboratory Investigations

E. Pulmonary Assessment

• Spirometry with bronchodilator reversibility
• Fractional exhaled nitric oxide (FeNO) if asthma suspected
• (Remember: 80% of allergic asthma patients have co-existing allergic rhinitis)

Step 3: Treatment - Stepwise Approach

Pillar 1: Allergen Avoidance (Primary Prevention)

• House dust mite: Allergen-impermeable mattress/pillow covers; humidity <50%; hot water washing of bedding (>130°F); vacuum with HEPA filter
• Moulds: Dehumidification; treat window/shower areas with dilute bleach; avoid indoor plants in bedroom
• Cockroaches: Extermination, sealing food sources
• Pet dander: Ideally rehome; HEPA air purifier; exclude from bedroom; regular bathing of pets
• Pollen: Air conditioning (filtered), close windows during high pollen season

Pillar 2: Pharmacotherapy

Step 1 - Mild/Intermittent Disease

• Cetirizine 10 mg OD
• Levocetirizine 5 mg OD
• Loratadine 10 mg OD
• Desloratadine 5 mg OD
• Fexofenadine 180 mg OD

Antihistamines are most effective for sneezing, rhinorrhea, and pruritus. Their benefit diminishes with continuous allergen exposure (perennial AR). Provide only 20-30% symptom reduction.

• Azelastine nasal spray
• Olopatadine nasal spray

Step 2 - Moderate/Persistent Disease (First-line for this patient)

• Provide 50-90% symptom reduction vs. 20-30% for antihistamines
• Treatment of choice for moderate-severe or perennial AR
• Also address turbinate hypertrophy - INCSs directly reduce mucosal edema
• If adding antihistamine to INCS, prefer intranasal antihistamine over oral

• Montelukast 10 mg OD - efficacy comparable to antihistamines; useful add-on
• Zileuton 1200 mg BD; Zafirlukast 20 mg BD (alternatives)
• Particularly useful in Samter's triad (ASA-exacerbated disease)

• Isotonic or hypertonic saline BD-TDS
• Mechanical clearance of allergens and mucus; enhances ciliary function
• Evidence-based adjunct in both AR and CRS

• Pseudoephedrine 30-60 mg q4-6h (max 240 mg/day)
• Use for acute flares; risk of rebound congestion with prolonged use

• Mast cell stabilizer; less effective than INCS
• Useful preventively (pre-exposure to triggers), especially in mild-moderate disease
• Requires QID dosing; less practical

Step 3 - Severe/Refractory Disease

• Methylprednisolone taper (e.g., 8mg QID x1d → 4mg QID x2d → taper over 6 days)
• Reserved for severe exacerbations; acute control before surgery

• For rhinorrhea-predominant symptoms; useful in infectious rhinitis component

Antibiotics (for infectious exacerbations of CRS):

• First line: Amoxicillin 500 mg TDS OR Amoxicillin-clavulanate 875/125 mg BD x 7 days
• Severe (fever >39°C, immunocompromised, recent abx use): Amoxicillin-clavulanate 2000/125 mg BD
• Penicillin allergy: Doxycycline 100 mg BD OR Levofloxacin 500 mg OD OR Moxifloxacin 400 mg OD
• Avoid: macrolides, 2nd/3rd generation cephalosporins (high resistance rates)
• Note: Watchful waiting acceptable for 7-10 days first; 85% resolve without antibiotics

Pillar 3: Immunotherapy (Definitive/Disease-Modifying Therapy)

• Indicated: Failed adequate pharmacotherapy OR desire for durable benefit
• Duration: 3-5 years total (build-up phase: weekly injections escalating over months; maintenance: monthly)
• Evidence: Multiple systematic reviews demonstrate significant reduction in rhinitis/rhinoconjunctivitis symptoms, QOL improvement, reduced medication use (Cummings ORL)
• Also prevents new sensitizations and reduces risk of asthma development
• Contraindications: Poorly controlled asthma, active autoimmune disease, malignancy, pregnancy (initiation), beta-blocker use (relative)
• Observe for 30 minutes post-injection (risk of anaphylaxis, rate 0.1%; fatalities extremely rare)

• FDA-approved for grass and house dust mite (tablets)
• Better safety profile than SCIT; growing acceptance
• Options: Grass pollen tablets, HDM tablets (Odactra/Acarizax)

Pillar 4: Biologics (For Refractory CRS with Nasal Polyps / Type 2 Inflammation)

• Reserve for: recurrent disease post-FESS, or comorbidities precluding surgery
• Tezepelumab (anti-TSLP, NEJM 2025 Phase III RCT - PMID 40106374) is emerging as another option

Recent evidence (Cai S et al., Allergy 2025, PMID 39985317 - meta-analysis): Biologics demonstrate superior efficacy and safety in CRSwNP in real-world settings.

Pillar 5: Surgical Options

For Turbinate Hypertrophy (if medical therapy fails):

• Mucosal redundancy or bony turbinate hypertrophy will NOT respond to medical therapy - these patients are surgical candidates
• Do NOT perform total turbinectomy - risks "empty nose syndrome" (atrophic rhinitis, paradoxical obstruction, chronic dryness/crusting)

1. Partial inferior turbinectomy (submucous resection)
2. Turbinoplasty (modified Mabry technique - preferred; preserves mucociliary function)
3. Radiofrequency volume reduction (RFVTR/Coblation) - minimally invasive, good functional preservation
4. Laser-assisted turbinoplasty (Holmium:YAG or KTP)
5. Microdebrider-assisted turbinoplasty
6. Cryosurgery
7. Infrared coagulation / electrical coagulation

For Chronic Rhinosinusitis (if medical therapy fails - 3+ months of maximal therapy):

• Opens OMC; removes obstructing tissue; improves mucociliary drainage
• Performed endoscopically (endonasal, no skin incisions)
• Evidence: Benefits patients with recurrent acute sinusitis and CRS refractory to medical treatment
• Post-operative saline irrigations + INCS maintenance essential
• Note: Even with aggressive therapy, patients with severe Type 2 eosinophilic inflammation may have early recurrence with nasal polyps

When to Refer to ENT (Goldman-Cecil Table 394-7)

• Temperature >39°C with orbital edema, severe headache, visual disturbance, altered mental status, meningeal signs (complications of acute sinusitis - emergency)
• Failure to respond to >2 courses of antimicrobial therapy
• Anatomic abnormalities, nosocomial infection
• Immunocompromised or multiple comorbidities
• Unusual/resistant pathogens
• Fungal sinusitis or granulomatous disease
• Recurrent episodes suggesting chronic sinusitis (this patient)

Summary Management Algorithm for this Patient

STEP 1: Confirm CRS + Allergic Background
  → Nasal endoscopy + allergy testing (SPT/serum IgE)
  → CBC, IgG/IgA/IgM, ANCA (exclude GPA/CVID)
  → Spirometry (co-existing asthma screen)

STEP 2: Allergen Avoidance + Education

STEP 3: Pharmacotherapy
  → INCS (mometasone/fluticasone) + nasal saline irrigation (daily)
  → Add: montelukast 10mg OD + 2nd gen antihistamine PRN
  → Antibiotic course only during acute bacterial exacerbations

STEP 4: Persist 3 months → reassess
  If adequate control → continue + consider SLIT/SCIT

STEP 5: If inadequate control → ENT referral
  → Nasal endoscopy + CT review (Lund-Mackay)
  → Consider: FESS + turbinate reduction
  → Post-surgical INCS maintenance

STEP 6: CRSwNP/Type 2 refractory disease
  → Dupilumab / Omalizumab / Mepolizumab

• Goldman-Cecil Medicine (International Edition), Chapter 394 (Rhinitis, Sinusitis, Rhinosinusitis) - Primary reference
• Cummings Otolaryngology Head & Neck Surgery, Chapters 35, 29
• Scott-Brown's Otorhinolaryngology, Vol. 1 & 2
• Recent: Cai S et al. Allergy 2025 [PMID 39985317] - Biologics meta-analysis; Lipworth BJ et al. NEJM 2025 [PMID 40106374] - Tezepelumab RCT in CRSwNP